Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.27 +0.7%	$0.26	$0.20 ▼ $1.48	$71.42M	2.86	1.82 million shs	327,710 shs
CGTX Cognition Therapeutics	$0.25 +2.1%	$0.36	$0.22 ▼ $2.54	$15.41M	1	2.62 million shs	560,309 shs
JSPR Jasper Therapeutics	$5.68 +11.2%	$4.54	$3.13 ▼ $26.84	$85.33M	2.74	295,705 shs	584,432 shs
PDSB PDS Biotechnology	$1.40 +2.2%	$1.23	$0.85 ▼ $4.42	$63.99M	1.4	487,057 shs	370,153 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+0.74%	-0.47%	+3.80%	-49.43%	-72.96%
CGTX Cognition Therapeutics	+2.05%	-21.08%	-40.41%	-45.35%	-87.87%
JSPR Jasper Therapeutics	+11.15%	+16.63%	+10.29%	-4.22%	-76.55%
PDSB PDS Biotechnology	+2.19%	-10.83%	+11.11%	+5.26%	-52.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.7715 of 5 stars	4.2	3.0	3.2	0.8	0.0
CGTX Cognition Therapeutics	3.0603 of 5 stars	3.5	3.0	2.2	2.5	1.3
JSPR Jasper Therapeutics	2.2453 of 5 stars	3.5	1.0	3.4	1.7	0.6
PDSB PDS Biotechnology	1.9251 of 5 stars	3.7	3.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	455.96% Upside
CGTX Cognition Therapeutics	3.00	Buy	$5.63	2,162.67% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.22	995.46% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	542.86% Upside

Current Analyst Ratings Breakdown

Latest CGTX, ADAP, PDSB, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/27/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $13.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/24/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.40	N/A	N/A	$0.17 per share	1.61
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.76 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
CGTX Cognition Therapeutics	-$25.79M	-$0.74	N/A	N/A	N/A	N/A	-150.93%	-100.82%	8/14/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)
PDSB PDS Biotechnology	-$42.94M	-$0.94	N/A	N/A	N/A	N/A	-139.57%	-67.22%	8/12/2025 (Estimated)

Latest CGTX, ADAP, PDSB, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
3/27/2025	Q4 2024	PDSB PDS Biotechnology	-$0.29	-$0.21	+$0.08	-$0.21	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/20/2025	Q4 2024	CGTX Cognition Therapeutics	-$0.16	-$0.17	-$0.01	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CGTX Cognition Therapeutics	N/A	2.11	2.11
JSPR Jasper Therapeutics	N/A	7.61	7.61
PDSB PDS Biotechnology	0.55	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CGTX Cognition Therapeutics	43.35%
JSPR Jasper Therapeutics	79.85%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
CGTX Cognition Therapeutics	20.75%
JSPR Jasper Therapeutics	2.70%
PDSB PDS Biotechnology	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	261.52 million	224.05 million	Optionable
CGTX Cognition Therapeutics	20	61.99 million	32.93 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
PDSB PDS Biotechnology	20	45.71 million	33.86 million	Optionable

CGTX, ADAP, PDSB, and JSPR Headlines

Recent News About These Companies

PDS Biotechnology files to sell 9.82M shares of common stock for holders

May 28 at 2:34 AM | msn.com

PDS Biotechnology (NASDAQ:PDSB) Raised to Hold at Wall Street Zen

May 26, 2025 | americanbankingnews.com

Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"

May 26, 2025 | marketbeat.com

Q2 EPS Estimates for PDS Biotechnology Increased by B. Riley

May 24, 2025 | marketbeat.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...

May 23, 2025 | uk.finance.yahoo.com

B. Riley Increases Earnings Estimates for PDS Biotechnology

May 23, 2025 | americanbankingnews.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025 | globenewswire.com

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses

May 16, 2025 | uk.investing.com

Data and sensing technology: Increases the value of PDS

May 16, 2025 | miningreview.com

PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

May 15, 2025 | finance.yahoo.com

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

EMV Capital portfolio company PDS Biotech advances cancer trial

May 15, 2025 | proactiveinvestors.co.uk

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 14, 2025 | globenewswire.com

Insights Ahead: PDS Biotechnology's Quarterly Earnings

May 14, 2025 | benzinga.com

PDS Biotechnology (PDSB) to Release Earnings on Wednesday

May 11, 2025 | marketbeat.com

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025 | globenewswire.com

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 8, 2025 | globenewswire.com

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 7, 2025 | globenewswire.com

Why PDS Biotechnology Corporation’s (PDSB) Stock Is Down 5.76%

May 7, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, ADAP, PDSB, and JSPR Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 +0.00 (+0.74%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.28 +0.01 (+2.89%)

As of 05/29/2025 07:33 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Cognition Therapeutics NASDAQ:CGTX

$0.25 +0.01 (+2.05%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.25 0.00 (-0.64%)

As of 05/29/2025 07:47 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Jasper Therapeutics NASDAQ:JSPR

$5.68 +0.57 (+11.15%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$5.74 +0.06 (+0.97%)

As of 05/29/2025 07:57 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

PDS Biotechnology NASDAQ:PDSB

$1.40 +0.03 (+2.19%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.41 +0.01 (+0.43%)

As of 05/29/2025 07:50 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time